
    
      The purpose of Phase 1 is to determine a maximum tolerated dose (MTD) for KB004 when
      administered to subjects with hematologic malignancies who meet the entry criteria. Phase 1
      has completed enrollment July of 2014, the recommended Phase 2 dose is 250 mg. AML 20 mg
      Cohort completed enrollment Dec 2014.

      The purpose of Phase 2 is to characterize preliminary clinical activity. The Phase 2 portion
      of the study consists of two parts:

        -  Part A: Subjects with AML or MDS who meet the entry criteria

        -  Part B: Subjects with MF who meet the entry criteria
    
  